Meet Our Advisory Board

Monument Tx’s Advisory Board is comprised of a highly experienced team of scientific professionals with a wide range of experience across the pharmaceutical and biotechnology sectors.

Dr Robin Bannister
Dr Robin Bannister
A successful drug development entrepreneur who focuses on the discovery of novel biology based on existing drugs.

Professor Ed Bullmore
Professor Ed Bullmore
Head of the Department of Psychiatry, University of Cambridge. Ed has authored more than 500 publications, has 15 years’ experience in the pharmaceutical industry and is the author of “The Inflamed Mind”.
Dr Robert Gristwood
Dr Robert Gristwood
Founder and Chief Scientist at Acacia Pharma. Robert has worked within the pharmaceutical industry for more than 30 years and been responsible for many innovative products.
Dr Ann Hayes
Dr Ann Hayes
Consultant to the pharmaceutical industry with many years’ experience of the pharmaceutical / biotechnology / digital health industry.

Fiona Cree
Fiona Cree
Fiona is COO of Cambridge Cognition and leads the Clinical Science and Operations teams. Twenty-five years’ experience in multi-national pharmaceutical companies and biotech SMEs, including a biotech focusing on development of a drug and diagnostic for Alzheimer’s disease.
Dr Steven Powell
Dr Steven Powell
Steven graduated in microbiology from the University of Wales and was awarded a PhD from the University of Aberdeen. He has over thirty years operational and investment experience in pharmaceutical and healthcare companies in the UK, USA and Scandinavia.
Professor Trevor Robbins
Professor Trevor Robbins
Professor of Cognitive Neuroscience and former Head of the Department of Psychology at the University of Cambridge.

Dr Stephen Wright
Dr Stephen Wright
Consultant in Drug Development, previously CMO, Head of R&D and Main Board Director at GW Pharma, and Sen VP of Development and Board Director of Ipsen.
Dr CD Nigel Toseland
Dr CD Nigel Toseland
Toxicological pathologist and fellow of the Royal College of Pathologists with over 30 years’ experience in the pharmaceutical industry. Broad therapeutic experience advising companies on pre-clinical development, expert toxicology overviews and conducting due diligence for licensing activities.
Dr Michael Sand
Dr Michael Sand
Michael has 35 years’ experience in the pharmaceutical industry, focused on developing novel compounds for serious mental illness. He currently serves as an Independent Consultant to the NIMH.